糖心原创

Home⇛Health Sciences Journal⇛vol. 14 no. 2 (2025)

Saccharomyces boulardii versus Bacilus clausii for the treatment of acute diarrhea: a systematic review and meta – analysis

Jose Ronilo G. Juangco | Maribel Emma Co-Hidalgo | Nanette Y. Ramilo-Cruz | Raymond Oliver A. Cruz | Kathryn Floro-Cruz | Riezel Vanessa Abdon | Ma. Leyhl Ann Nierves | Shalemar Kasan | Jasmine Sanghilan

Discipline: medicine by specialism

 

Abstract:

Introduction Diarrhea remains a significant cause of childhood mortality, despite the availability of simple treatment solutions. Probiotics have emerged as a potential therapeutic modality for the treatment of diarrhea. Objective This study aimed to evaluate the comparative efficacy of Saccharomyces boulardii and Bacillus clausii in the treatment of acute diarrhea Methods A systematic search of MEDLINE, EBSCO, Clinical Key, the Cochrane Library, Academia, and Google Scholar was conducted to identify clinical trials using Saccharomyces boulardiiand Bacillus clausii as interventions. The primary outcome measure was the duration of diarrhea. Risk of bias was assessed using the CEBM Critical Appraisal tool and the Cochrane Collaboration tool. Data were analyzed using RevMan 5.4 software. Results Four studies involving 411 participants were included in the systematic review and meta-analysis. All studies demonstrated a weighted mean decrease in the duration of diarrhea, ranging from 4.70 to 25.20 hours, favoring Saccharomyces boulardii. The pooled analysis revealed a significant reduction of 24.98 hours in the duration of diarrhea, favoring Saccharomyces boulardii (p < 0.0001). Conclusion A systematic review and meta-analysis of four clinical trials showed that Saccharomyces boulardii is more effective than Bacilus clausii in reducing the duration of diarrhea among patients with acute diarrhea. These findings support the use of Saccharomyces boulardii as a preferred probiotic intervention for the treatment of acute diarrhea.



References:

  1. WHO Maternal and Child Epidemiology Estimation Group (MCEE) provisional estimates. 2015.
  2. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, Rudan I, Campbell H, Cibulskis R, Li M, Mathers C, Black RE; Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 2012;379(9832):2151– 61.
  3. Factsheet. Diarrhoeal disease [Internet]. WHO Media Centre 2017 [cited 2022 Nov 13]. Available from:
  4. World Gastroenterology Organisation. WGO Global Guidelines: Probiotics and Prebiotics. October 2011.
  5. Canani RB, Cirillo P, Terrin G, Cesarano L, Spagnuolo MI, De Vincenzo A, Albano F, Passariello A, De Marco G, Manguso F, Guarino A. Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ 2007 Aug 18;335(7615):340. doi: 10.1136/bmj.39272.581736.55.
  6. McFarland LV. Common organisms and probiotics: Saccharomyces boulardii. In: The Microbiota in Gastrointestinal Pathophysiology. 2017.
  7. Vandenplas Y, Brunser O, Szajewska H. Saccharomyces boulardii in childhood. Eur J Pediatr 2009;168(3):253–65.
  8. Jayanthi N, Sudha RM. Bacillus clausii–The probiotic of choice in the treatment of diarrhoea. J Yoga Phys Ther 2015 Oct 1;5(4):1.
  9. Cochrane Handbook for Systematic Reviews of Interventions [Internet]. [cited 2022 Nov 13]. Available from:
  10. PRISMA Checklist [Inter net]. [cited 2022 Nov 13]. Available from:
  11. Cochrane Handbook: Identifying and measuring heterogeneity [Internet]. [cited 2022 Nov 13]. Available from:
  12. Vineeth S, Saireddy S, Keerthi T, Mantada PK. Efficacy of Bacillus clausii and Saccharomyces boulardii in treatment of acute rotaviral diarrhea in pediatric patients. Indonesian J Clin Pharm. 2017 Jun 1;6(2):91–8. doi: 10.15416/ijcp.2017.6.2.91
  13. Vidjeadevan D, Vinoth S, Ramesh S. Role of Saccharomyces boulardii and Bacillus clausii in reducing the duration of diarrhea: a three-armed randomized controlled trial. Int J Contemp Pediatr 2018;5(5):1811–4. doi: 10.18203/2349- 3291.ijcp20183511. Available from:
  14. Canani RB, Cirillo P, Terrin G, Cesarano L, Spagnuolo MI, De Vincenzo A, Albano F, Passariello A, De Marco G, Manguso F, Guarino A. Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ 2007 Aug 18;335(7615):340. doi:10.1136/bmj.39272.581736.55.
  15. Vidjeadevan D, Ramesh S, Vinoth S. Role of Saccharomyces boulardii and Bacillus clausii in children with acute diarrhea—a randomized control trial. J Med Sci Clin Res 2017;5:30910–4.
  16. UNICEF. Diarrhea data [Internet]. 2021 [cited 2021 Dec 23]. Available from:
  17. Guarner F, Khan AG, Garisch J, Eliakim R, Gangl A, Thomson A, Krabshuis J, Lemair T, Kaufmann P, de Paula JA, Fedorak R, Shanahan F, Sanders ME, Szajewska H, Ramakrishna BS, Karakan T, Kim N; World Gastroenterology Organization. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. J Clin Gastroenterol 2012 Jul;46(6):468–81. doi:10.1097/MCG.0b013e3182549092.
  18. Blehaut H, Massot J, Elmer GW, Levy RH. Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm Drug Dispos 1989;10:353–64.
  19. Zbinden R. Inhibition of Saccharomyces boulardii (nom. inval.) on cell invasion of Salmonella typhimurium and Yersinia enterocolitica. Microb Ecol Health Dis 1999;11(3):158–62.
  20. Czerucka D, Rampal P. Experimental effects of Saccharomyces boulardii on diarrhoeal pathogens. Microbes Infect 2002;4:733–9.
  21. Geyik MF, Aldemir M, Hosoglu S, et al. The effects of Saccharomyces boulardii on bacterial translocation in rats with obstructive jaundice. Ann R Coll Surg Engl 2006;88(2):176–80.
  22. Buts JP, Bernasconi P, Vaerman JP. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 1990;35(2):251–6.
  23. Buts J, De Keyser N, De Raedemaeker L. Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines. Pediatr Res 1994;36:522–7.
  24. Sougioultzis S, Simeonidis S, Bhaskar KR, Chen X, Anton PM, Keates S, et al. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaBmediated IL-8 gene expression. Biochem Biophys Res Commun 2006;343:69–76.
  25. Juangco JRG, Cruz ROA, Hidalgo MEC, Floro-Cruz K, Abdon RV. Effectiveness of Saccharomyces boulardii on diarrhea, a systematic review and meta-analysis. Health Sci J. 2021;10(1):16–24. Available from:
  26. Szajewska H, Guarino A, Hojsak I, Indrio F, Kolacek S, Orel R, Salvatore S, Shamir R, van Goudoever JB, Vandenplas Y, Weizman Z, Zalewski BM. Working Group on Probiotics and Prebiotics of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Use of probiotics for the management of acute gastroenteritis in children: an update. J Pediatr Gastroenterol Nutr 2020 Aug;71(2):261–9. doi: 10.1097/ MPG.0000000000002751. PMID: 32349041.
  27. Li Z, Zhu G, Li C, Lai H, Liu X, Zhang L. Which probiotic is the most effective for treating acute diarrhea in children? A Bayesian network meta-analysis of randomized controlled trials. Nutrients 2021;13:4319. doi:10.3390/nu13124319
  28. Sniffen JC, McFarland LV, Evans CT, Goldstein EJC. Choosing an appropriate probiotic product for your patient: an evidence-based practical guide. PLoS One 2018;13(12):e0209205. doi:10.1371/journal.pone.0209205

Tools


Copyright © 2026  糖心原创 Exclusively distributed by